Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis.

Ophthalmology and therapy·2026
Same author

Saliva as a noninvasive diagnostic for ocular sarcoidosis.

Journal of leukocyte biology·2026
Same author

Oral cyclophosphamide as part of the treatment regimen in patients with nonparaneoplastic autoimmune retinopathy secondary to birdshot chorioretinopathy.

Oman journal of ophthalmology·2026
Same author

Descemet Membrane Anterior Keratoplasty With BrightMEM Corneal Allograft: An Innovative Technique for Treatment of Nonhealing Diseases of the Ocular Surface.

Cornea·2026
Same author

How to interpret low-dose valacyclovir for postherpetic neuralgia in the Zoster Eye Disease Study-a randomized clinical trial.

Annals of translational medicine·2026
Same author

A Critical Evaluation of Concentration Proxies in SIMS Diffusion Studies.

Analytical chemistry·2026
Same journal

Diverse Conjunctival Adverse Events Associated with Tisotumab Vedotin.

Ophthalmology·2026
Same journal

The Answer Is Blowing in the Wind: Uncovering Hidden Glaucoma Risk Factors.

Ophthalmology·2026
Same journal

Nonsteroidal Anti-inflammatory Drug Use Reduces the Risk of Age-Related Macular Degeneration in Electronic Health Record Analysis: Signal or Solution?

Ophthalmology·2026
Same journal

Metastasis of Nasopharyngeal Squamous Cell Carcinoma to the Angle.

Ophthalmology·2026
Same journal

Endocrine Mucin-Producing Sweat Gland Carcinoma of Eyelid.

Ophthalmology·2026
Same journal

Multimodal Imaging of Optic Nerve Invasion in Unilateral Retinoblastoma.

Ophthalmology·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking (TXL) for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking (TXL) for Myopia

Published on: January 6, 2018

Scleritis therapy.

Maite Sainz de la Maza1, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez

  • 1Institute Clinic of Ophthalmology, Hospital Clinic of Barcelona, Barcelona, Spain.

Ophthalmology
|October 22, 2011
PubMed
Summary
This summary is machine-generated.

Successful scleritis treatment varies by disease type and severity. Mild idiopathic cases may respond to NSAIDs, while severe inflammation may require SAIDs. Systemic or necrotizing scleritis often necessitates immunomodulatory therapy or biologics.

Related Experiment Videos

Last Updated: May 28, 2026

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking (TXL) for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking (TXL) for Myopia

Published on: January 6, 2018

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Scleritis is an inflammatory eye condition with diverse clinical presentations.
  • Identifying effective treatment strategies is crucial for managing scleritis and preventing vision loss.
  • Noninfectious anterior scleritis encompasses various subtypes requiring tailored therapeutic approaches.

Purpose of the Study:

  • To identify factors predicting successful treatment outcomes in patients with noninfectious anterior scleritis.
  • To correlate specific scleritis manifestations with responses to different anti-inflammatory and immunosuppressive therapies.

Main Methods:

  • Retrospective case series analysis of 392 patients with noninfectious anterior scleritis.
  • Review of electronic health records to assess patient characteristics, ocular disease features, systemic associations, and medication responses.
  • Evaluation of treatment success with nonsteroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs (SAIDs), immunomodulatory therapy (IMT), and biologic response modifiers (BRMs).

Main Results:

  • NSAIDs were effective for idiopathic diffuse/nodular scleritis with low inflammation (≤2+) or no ocular complications.
  • SAIDs showed success in idiopathic diffuse/nodular scleritis with high inflammation (>2+).
  • Immunomodulatory therapy (IMT) or biologics (BRMs) were associated with diffuse/nodular scleritis with systemic disease; IMT was particularly effective for necrotizing scleritis, especially with alkylating agents.

Conclusions:

  • Treatment selection for noninfectious anterior scleritis should be guided by disease severity and specific characteristics.
  • Mild idiopathic scleritis may respond to NSAIDs, moderate to severe inflammation to SAIDs.
  • Systemic associations and necrotizing forms of scleritis often require more potent immunosuppressive agents like IMT or BRMs.